GlassScriptPhysician profile
Mark Richard Mcandrew
NPI 1740281674
$13,417.43
in general payments reported to CMS, 2019-2025
21 companies · $8,185 in 2025
The $8,185 reported for 2025 was more than what 94% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,275 · 2021: $136 · 2022: $74.73 · 2023: $1,898 · 2024: $849 · 2025: $8,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,000 · Food and Beverage: $2,590 · Travel and Lodging: $1,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,000.00 |
| Food and Beverage | $2,590.21 |
| Travel and Lodging | $1,341.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,857.82 | 2023-2025 | Da Vinci Surgical System |
| W. L. Gore & Associates, INC. | $4,631.33 | 2019-2025 | Gore Bio-A Tissue Reinforcement, Seamguard, Gore Viabahn Endoprosthesis |
| Organogenesis INC. | $153.49 | 2024 | Affinity |
| Cook Medical LLC | $148.00 | 2025 | Zenith |
| Ethicon US, LLC | $106.31 | 2019-2025 | Stratafix |
| Smith+Nephew, INC. | $85.62 | 2019-2025 | Stravix, Collagenase Santyl |
| Braintree Laboratories, INC. | $80.23 | 2022-2024 | Sutab, Suflave |
| Medtronic, INC. | $64.86 | 2021-2023 | Venaseal |
| Abbvie INC. | $40.72 | 2024 | |
| Solventum Corporation | $32.52 | 2024 | Activ.A.C. |
| Davol INC. | $30.77 | 2024 | Phasix Mesh |
| Conmed Corporation | $29.38 | 2025 | Conmed Specimen Retrieval, Airseal |
| Depuy Synthes Sales INC. | $28.54 | 2019 | |
| Biotissue Holdings INC. | $19.35 | 2024 | |
| Innocoll Pharmaceuticals Limited | $17.97 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $17.66 | 2025 | |
| Heartflow, INC. | $16.74 | 2024 | |
| Merck Sharp & Dohme LLC | $15.46 | 2025 | Bridion |
| Kci USA, INC. | $14.08 | 2019 | |
| Kerecis Limited | $13.95 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Bioventus LLC | $12.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mcandrew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.